Verastem (GB:0LOV)
UK Market

Verastem Stock Analysis & Ratings

GB:0LOV Stock Chart & Stats

Day’s Range$1.33 - $1.33
52-Week Range$0.00 - $0.00
Previous Close$1.2
Average Volume (3M)735.00
Market Cap$247.86M
P/E RatioN/A
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)0.00



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Verastem’s market cap?
    Verastem’s market cap is $247.86M.
      What is Verastem’s price target?
      The average price target for Verastem is $5.67. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $6.00 ,the lowest forecast is $5.00. The average price target represents 326.32% Increase from the current price of $1.33.
        What do analysts say about Verastem?
        Verastem’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
          When is Verastem’s upcoming earnings report date?
          Verastem’s upcoming earnings report date is Aug 10, 2022 which is in 81 days.
            How were Verastem’s earnings last quarter?
            Verastem released its earnings results on May 09, 2022. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.082 by -$0.008.
              Is Verastem overvalued?
              According to Wall Street analysts Verastem’s price is currently Undervalued.
                Does Verastem pay dividends?
                Verastem does not currently pay dividends.
                What is Verastem’s EPS estimate?
                Verastem’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Verastem have?
                Verastem has 186,360,000 shares outstanding.
                  What happened to Verastem’s price movement after its last earnings report?
                  Verastem reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.082. Following the earnings report the stock price went same 0%.
                    Which hedge fund is a major shareholder of Verastem?
                    Among the largest hedge funds holding Verastem’s share is Graham Capital Management, L.P.. It holds Verastem’s shares valued at N/A.


                      Verastem Stock Analysis

                      The Verastem stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description


                      Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

                      Similar Stocks
                      Price & Change
                      TG Therapeutics
                      Daré Bioscience

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis